Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Amortization of Deferred Charges (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $642000.0 as the latest value for Q4 2025.

  • Quarterly Amortization of Deferred Charges changed N/A to $642000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, up 18.11% year-over-year, with the annual reading at $2.4 million for FY2025, 18.11% up from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was $642000.0 at Inhibrx Biosciences, up from $638000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $1.2 million in Q4 2023, with the low at $533000.0 in Q1 2025.
  • Average Amortization of Deferred Charges over 3 years is $873750.0, with a median of $732500.0 recorded in 2024.
  • Peak annual rise in Amortization of Deferred Charges hit 23.94% in 2025, while the deepest fall reached 57.09% in 2025.
  • Over 3 years, Amortization of Deferred Charges stood at $1.2 million in 2023, then crashed by 34.0% to $823000.0 in 2024, then dropped by 21.99% to $642000.0 in 2025.
  • According to Business Quant data, Amortization of Deferred Charges over the past three periods came in at $642000.0, $638000.0, and $626000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.